Do hepatic insulin resistance and hyperglycemia drive increased de novo lipogenesis and VLDL export that lead to metabolic-associated fatty liver and elevated ALT?

The metabolic sequence by which liver insulin resistance and hyperglycemia drive the progression of metabolic-associated steatotic liver disease (MASLD) and elevated liver enzymes is well-supported by clinical and mechanistic research. In healthy states, insulin suppresses glucose production and promotes fat storage; however, in the insulin-resistant liver, a "selective" signaling defect occurs where the liver fails to stop producing glucose but continues to synthesize fat at an accelerated rate.

Mechanistic pathways of lipogenesis

The promotion of de novo lipogenesis (DNL) occurs through two primary transcriptional pathways that remain active or are hyper-activated despite systemic insulin resistance:

• SREBP-1c Activation: Even when the liver becomes resistant to insulin’s ability to suppress gluconeogenesis, the insulin-mediated activation of Sterol Regulatory Element-Binding Protein 1c (SREBP-1c) often remains intact. This leads to the upregulation of key lipogenic enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC).
• ChREBP Signaling: Elevated blood glucose levels independently stimulate the Carbohydrate Response Element-Binding Protein (ChREBP). This pathway provides a direct link between hyperglycemia and the conversion of excess glucose into fatty acids, providing both the signaling stimulus and the carbon substrate for fat synthesis.
• DNL Contribution: In patients with MASLD, stable isotope tracer studies indicate that DNL is elevated 2-to-3-fold compared to healthy individuals, accounting for approximately 15–25% of the total hepatic triglyceride pool.

VLDL export and systemic dyslipidemia

The liver initially attempts to manage this increased lipid burden by increasing the assembly and secretion of triglyceride-rich VLDL (specifically VLDL1) particles:

• Inhibition Loss: Under normal conditions, insulin inhibits VLDL secretion. In insulin-resistant states, this inhibition is lost, resulting in an overproduction of large, triglyceride-rich VLDL1.
• Steatosis Transition: While VLDL export initially increases as a compensatory mechanism, it often cannot keep pace with the high rates of DNL and fatty acid uptake. When the rate of lipid synthesis exceeds the export capacity (often due to ER stress or impaired apolipoprotein B-100 synthesis), lipids accumulate as droplets within hepatocytes, leading to clinical steatosis.

Clinical implications and liver injury

The accumulation of intrahepatic lipids, particularly lipotoxic intermediates like diacylglycerols and ceramides, triggers cellular stress and inflammatory cascades:

• Hepatocellular Damage: Excess fat leads to mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum stress. This progression causes hepatocyte membrane damage or ballooning.
• ALT Elevation: As hepatocytes become damaged or necrotic, alanine aminotransferase (ALT) leaks into the systemic circulation. Large cohort studies (e.g., NHANES) demonstrate a robust correlation between markers of insulin resistance (HOMA-IR), the degree of hepatic steatosis, and serum ALT levels.

Bottom line

The claim is strongly supported by science. Hepatic insulin resistance and hyperglycemia synergistically drive de novo lipogenesis and VLDL overproduction. When these processes overwhelm the liver's export capacity, the resulting lipid accumulation causes the cellular injury reflected by elevated ALT levels in metabolic-associated fatty liver disease.